Loading…
Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy
Background This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical charac...
Saved in:
| Published in: | Infection 2024-10, Vol.52 (5), p.1941-1952 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c414t-c004fa15e787e7d58800afe1a5c0dd322901a89dc0555763c35779f14adfd2633 |
| container_end_page | 1952 |
| container_issue | 5 |
| container_start_page | 1941 |
| container_title | Infection |
| container_volume | 52 |
| creator | Pérez, Ariadna Montoro, Juan Chorão, Pedro Gómez, Dolores Guerreiro, Manuel Giménez, Estela Villalba, Marta Sanz, Jaime Hernani, Rafael Hernández-Boluda, Juan Carlos Lorenzo, Ignacio Navarro, David Solano, Carlos Ljungman, Per Piñana, José Luis |
| description | Background
This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical characteristics, and risk factors associated with lower respiratory tract disease (LRTD) progression and all-cause mortality.
Patients and methods
The study included 230 allo-SCT recipients diagnosed with hPIV between December 2013 and June 2023. Risk factors for the development of LRTD, disease severity, and mortality were analyzed. Ribavirin treatment was administered at physician discretion in 61 out of 230 cases (27%).
Results
Risk factors for LRTD progression in multivariate analysis were corticosteroids > 30 mg/day (Odds ratio (OR) 3.5, 95% Confidence Interval (C.I.) 1.3–9.4,
p
= 0.013), fever at the time of hPIV detection (OR 3.89, 95% C.I. 1.84–8.2,
p
|
| doi_str_mv | 10.1007/s15010-024-02213-0 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_858107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3119852781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-c004fa15e787e7d58800afe1a5c0dd322901a89dc0555763c35779f14adfd2633</originalsourceid><addsrcrecordid>eNp9ks9uFSEUxonR2Gv1BVwYEjduRg8DDODONGpNmtSFuiVc5kylzjAjMJr6Ar623N7bNjHRBeHf7_sOnHyEPGXwkgGoV5lJYNBAK-poGW_gHtkwwU0DRvH7ZAMcoNGs7Y7Io5wvAUAaoR6SI647yY2UG_L7fC1-npDOAz1dJxfpR5dciMO4Yvzl6JeQ1kzrHn0Jc6wr6sZxvsCIwdNccKIex5GW5GJeRheLu-YS-rAEjCW_psucc9iOSMO0OF92pVLYuh8hVbfyFZNbrh6TB4MbMz45zMfk87u3n05Om7Pz9x9O3pw1XjBRGg8gBsckKq1Q9VJrADcgc9JD3_O2NcCcNr0HKaXquOdSKTMw4fqhbzvOj0mz980_cVm3dklhcunKzi7Yw9G3ukKrpWagKm_-yS9p7u9EN0K2Kyx0J6r2xV5bwe8r5mKnkHfdchHnNVsOQjLGhTEVff4XejmvKdZOWM6Y0bJVmlWq3VM-1ZYmHG6fw8DuImH3kbA1EvY6Ehaq6NnBet1O2N9KbjJQAX74Yr2KF5juav_H9g80KsSb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3119852781</pqid></control><display><type>article</type><title>Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>Pérez, Ariadna ; Montoro, Juan ; Chorão, Pedro ; Gómez, Dolores ; Guerreiro, Manuel ; Giménez, Estela ; Villalba, Marta ; Sanz, Jaime ; Hernani, Rafael ; Hernández-Boluda, Juan Carlos ; Lorenzo, Ignacio ; Navarro, David ; Solano, Carlos ; Ljungman, Per ; Piñana, José Luis</creator><creatorcontrib>Pérez, Ariadna ; Montoro, Juan ; Chorão, Pedro ; Gómez, Dolores ; Guerreiro, Manuel ; Giménez, Estela ; Villalba, Marta ; Sanz, Jaime ; Hernani, Rafael ; Hernández-Boluda, Juan Carlos ; Lorenzo, Ignacio ; Navarro, David ; Solano, Carlos ; Ljungman, Per ; Piñana, José Luis</creatorcontrib><description>Background
This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical characteristics, and risk factors associated with lower respiratory tract disease (LRTD) progression and all-cause mortality.
Patients and methods
The study included 230 allo-SCT recipients diagnosed with hPIV between December 2013 and June 2023. Risk factors for the development of LRTD, disease severity, and mortality were analyzed. Ribavirin treatment was administered at physician discretion in 61 out of 230 cases (27%).
Results
Risk factors for LRTD progression in multivariate analysis were corticosteroids > 30 mg/day (Odds ratio (OR) 3.5, 95% Confidence Interval (C.I.) 1.3–9.4,
p
= 0.013), fever at the time of hPIV detection (OR 3.89, 95% C.I. 1.84–8.2,
p
< 0.001), and absolute lymphocyte count (ALC) < 0.2 × 10
9
/L (OR 4.1, 95% C.I. 1.42–11.9,
p
= 0.009). In addition, the study found that ribavirin therapy significantly reduced progression to LRTD [OR 0.19, 95% C.I. 0.05–0.75,
p
= 0.018]. Co-infections (OR 5.7, 95% C.I. 1.4–23.5,
p
= 0.015) and ALC < 0.2 × 10
9
/L (OR 17.7, 95% C.I. 3.6–87.1,
p
< 0.001) were independently associated with higher day + 100 after hPIV detection all-cause mortality. There were no significant differences in all-cause mortality and infectious mortality at day + 100 between the treated and untreated groups.
Conclusion
ALC, corticosteroids, and fever increased the risk for progression to LRTD while ribavirin decreased the risk. However, mortality was associated with ALC and co-infections. This study supports further research of ribavirin therapy for hPIV in the allo-HSCT setting.</description><identifier>ISSN: 0300-8126</identifier><identifier>ISSN: 1439-0973</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-024-02213-0</identifier><identifier>PMID: 38653955</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Allografts ; Antiviral Agents - therapeutic use ; Cell number ; Community-Acquired Infections - drug therapy ; Community-Acquired Infections - mortality ; Community-Acquired Infections - virology ; Corticoids ; Corticosteroids ; Family Medicine ; Female ; Fever ; General Practice ; Health services ; Humans ; Impact analysis ; Infections ; Infectious Diseases ; Internal Medicine ; Lymphocytes ; Male ; Medicin och hälsovetenskap ; Medicine ; Medicine & Public Health ; Middle Aged ; Mortality ; Multivariate analysis ; Parainfluenza ; Paramyxoviridae Infections - drug therapy ; Paramyxoviridae Infections - mortality ; Respiratory tract ; Respiratory tract diseases ; Retrospective Studies ; Ribavirin ; Ribavirin - therapeutic use ; Risk Factors ; Stem cell transplantation ; Stem Cell Transplantation - adverse effects ; Stem cells ; Steroids ; Therapy ; Transplantation, Homologous - adverse effects ; Transplants & implants ; Treatment Outcome ; Viruses ; Young Adult</subject><ispartof>Infection, 2024-10, Vol.52 (5), p.1941-1952</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c414t-c004fa15e787e7d58800afe1a5c0dd322901a89dc0555763c35779f14adfd2633</cites><orcidid>0000-0001-8533-2562</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38653955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:155764864$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez, Ariadna</creatorcontrib><creatorcontrib>Montoro, Juan</creatorcontrib><creatorcontrib>Chorão, Pedro</creatorcontrib><creatorcontrib>Gómez, Dolores</creatorcontrib><creatorcontrib>Guerreiro, Manuel</creatorcontrib><creatorcontrib>Giménez, Estela</creatorcontrib><creatorcontrib>Villalba, Marta</creatorcontrib><creatorcontrib>Sanz, Jaime</creatorcontrib><creatorcontrib>Hernani, Rafael</creatorcontrib><creatorcontrib>Hernández-Boluda, Juan Carlos</creatorcontrib><creatorcontrib>Lorenzo, Ignacio</creatorcontrib><creatorcontrib>Navarro, David</creatorcontrib><creatorcontrib>Solano, Carlos</creatorcontrib><creatorcontrib>Ljungman, Per</creatorcontrib><creatorcontrib>Piñana, José Luis</creatorcontrib><title>Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy</title><title>Infection</title><addtitle>Infection</addtitle><addtitle>Infection</addtitle><description>Background
This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical characteristics, and risk factors associated with lower respiratory tract disease (LRTD) progression and all-cause mortality.
Patients and methods
The study included 230 allo-SCT recipients diagnosed with hPIV between December 2013 and June 2023. Risk factors for the development of LRTD, disease severity, and mortality were analyzed. Ribavirin treatment was administered at physician discretion in 61 out of 230 cases (27%).
Results
Risk factors for LRTD progression in multivariate analysis were corticosteroids > 30 mg/day (Odds ratio (OR) 3.5, 95% Confidence Interval (C.I.) 1.3–9.4,
p
= 0.013), fever at the time of hPIV detection (OR 3.89, 95% C.I. 1.84–8.2,
p
< 0.001), and absolute lymphocyte count (ALC) < 0.2 × 10
9
/L (OR 4.1, 95% C.I. 1.42–11.9,
p
= 0.009). In addition, the study found that ribavirin therapy significantly reduced progression to LRTD [OR 0.19, 95% C.I. 0.05–0.75,
p
= 0.018]. Co-infections (OR 5.7, 95% C.I. 1.4–23.5,
p
= 0.015) and ALC < 0.2 × 10
9
/L (OR 17.7, 95% C.I. 3.6–87.1,
p
< 0.001) were independently associated with higher day + 100 after hPIV detection all-cause mortality. There were no significant differences in all-cause mortality and infectious mortality at day + 100 between the treated and untreated groups.
Conclusion
ALC, corticosteroids, and fever increased the risk for progression to LRTD while ribavirin decreased the risk. However, mortality was associated with ALC and co-infections. This study supports further research of ribavirin therapy for hPIV in the allo-HSCT setting.</description><subject>Adult</subject><subject>Aged</subject><subject>Allografts</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cell number</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Community-Acquired Infections - mortality</subject><subject>Community-Acquired Infections - virology</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>Family Medicine</subject><subject>Female</subject><subject>Fever</subject><subject>General Practice</subject><subject>Health services</subject><subject>Humans</subject><subject>Impact analysis</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Medicin och hälsovetenskap</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Parainfluenza</subject><subject>Paramyxoviridae Infections - drug therapy</subject><subject>Paramyxoviridae Infections - mortality</subject><subject>Respiratory tract</subject><subject>Respiratory tract diseases</subject><subject>Retrospective Studies</subject><subject>Ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Risk Factors</subject><subject>Stem cell transplantation</subject><subject>Stem Cell Transplantation - adverse effects</subject><subject>Stem cells</subject><subject>Steroids</subject><subject>Therapy</subject><subject>Transplantation, Homologous - adverse effects</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>0300-8126</issn><issn>1439-0973</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9ks9uFSEUxonR2Gv1BVwYEjduRg8DDODONGpNmtSFuiVc5kylzjAjMJr6Ar623N7bNjHRBeHf7_sOnHyEPGXwkgGoV5lJYNBAK-poGW_gHtkwwU0DRvH7ZAMcoNGs7Y7Io5wvAUAaoR6SI647yY2UG_L7fC1-npDOAz1dJxfpR5dciMO4Yvzl6JeQ1kzrHn0Jc6wr6sZxvsCIwdNccKIex5GW5GJeRheLu-YS-rAEjCW_psucc9iOSMO0OF92pVLYuh8hVbfyFZNbrh6TB4MbMz45zMfk87u3n05Om7Pz9x9O3pw1XjBRGg8gBsckKq1Q9VJrADcgc9JD3_O2NcCcNr0HKaXquOdSKTMw4fqhbzvOj0mz980_cVm3dklhcunKzi7Yw9G3ukKrpWagKm_-yS9p7u9EN0K2Kyx0J6r2xV5bwe8r5mKnkHfdchHnNVsOQjLGhTEVff4XejmvKdZOWM6Y0bJVmlWq3VM-1ZYmHG6fw8DuImH3kbA1EvY6Ehaq6NnBet1O2N9KbjJQAX74Yr2KF5juav_H9g80KsSb</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Pérez, Ariadna</creator><creator>Montoro, Juan</creator><creator>Chorão, Pedro</creator><creator>Gómez, Dolores</creator><creator>Guerreiro, Manuel</creator><creator>Giménez, Estela</creator><creator>Villalba, Marta</creator><creator>Sanz, Jaime</creator><creator>Hernani, Rafael</creator><creator>Hernández-Boluda, Juan Carlos</creator><creator>Lorenzo, Ignacio</creator><creator>Navarro, David</creator><creator>Solano, Carlos</creator><creator>Ljungman, Per</creator><creator>Piñana, José Luis</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><orcidid>https://orcid.org/0000-0001-8533-2562</orcidid></search><sort><creationdate>20241001</creationdate><title>Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy</title><author>Pérez, Ariadna ; Montoro, Juan ; Chorão, Pedro ; Gómez, Dolores ; Guerreiro, Manuel ; Giménez, Estela ; Villalba, Marta ; Sanz, Jaime ; Hernani, Rafael ; Hernández-Boluda, Juan Carlos ; Lorenzo, Ignacio ; Navarro, David ; Solano, Carlos ; Ljungman, Per ; Piñana, José Luis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-c004fa15e787e7d58800afe1a5c0dd322901a89dc0555763c35779f14adfd2633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Allografts</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cell number</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Community-Acquired Infections - mortality</topic><topic>Community-Acquired Infections - virology</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>Family Medicine</topic><topic>Female</topic><topic>Fever</topic><topic>General Practice</topic><topic>Health services</topic><topic>Humans</topic><topic>Impact analysis</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Medicin och hälsovetenskap</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Parainfluenza</topic><topic>Paramyxoviridae Infections - drug therapy</topic><topic>Paramyxoviridae Infections - mortality</topic><topic>Respiratory tract</topic><topic>Respiratory tract diseases</topic><topic>Retrospective Studies</topic><topic>Ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Risk Factors</topic><topic>Stem cell transplantation</topic><topic>Stem Cell Transplantation - adverse effects</topic><topic>Stem cells</topic><topic>Steroids</topic><topic>Therapy</topic><topic>Transplantation, Homologous - adverse effects</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez, Ariadna</creatorcontrib><creatorcontrib>Montoro, Juan</creatorcontrib><creatorcontrib>Chorão, Pedro</creatorcontrib><creatorcontrib>Gómez, Dolores</creatorcontrib><creatorcontrib>Guerreiro, Manuel</creatorcontrib><creatorcontrib>Giménez, Estela</creatorcontrib><creatorcontrib>Villalba, Marta</creatorcontrib><creatorcontrib>Sanz, Jaime</creatorcontrib><creatorcontrib>Hernani, Rafael</creatorcontrib><creatorcontrib>Hernández-Boluda, Juan Carlos</creatorcontrib><creatorcontrib>Lorenzo, Ignacio</creatorcontrib><creatorcontrib>Navarro, David</creatorcontrib><creatorcontrib>Solano, Carlos</creatorcontrib><creatorcontrib>Ljungman, Per</creatorcontrib><creatorcontrib>Piñana, José Luis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez, Ariadna</au><au>Montoro, Juan</au><au>Chorão, Pedro</au><au>Gómez, Dolores</au><au>Guerreiro, Manuel</au><au>Giménez, Estela</au><au>Villalba, Marta</au><au>Sanz, Jaime</au><au>Hernani, Rafael</au><au>Hernández-Boluda, Juan Carlos</au><au>Lorenzo, Ignacio</au><au>Navarro, David</au><au>Solano, Carlos</au><au>Ljungman, Per</au><au>Piñana, José Luis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy</atitle><jtitle>Infection</jtitle><stitle>Infection</stitle><addtitle>Infection</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>52</volume><issue>5</issue><spage>1941</spage><epage>1952</epage><pages>1941-1952</pages><issn>0300-8126</issn><issn>1439-0973</issn><eissn>1439-0973</eissn><abstract>Background
This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical characteristics, and risk factors associated with lower respiratory tract disease (LRTD) progression and all-cause mortality.
Patients and methods
The study included 230 allo-SCT recipients diagnosed with hPIV between December 2013 and June 2023. Risk factors for the development of LRTD, disease severity, and mortality were analyzed. Ribavirin treatment was administered at physician discretion in 61 out of 230 cases (27%).
Results
Risk factors for LRTD progression in multivariate analysis were corticosteroids > 30 mg/day (Odds ratio (OR) 3.5, 95% Confidence Interval (C.I.) 1.3–9.4,
p
= 0.013), fever at the time of hPIV detection (OR 3.89, 95% C.I. 1.84–8.2,
p
< 0.001), and absolute lymphocyte count (ALC) < 0.2 × 10
9
/L (OR 4.1, 95% C.I. 1.42–11.9,
p
= 0.009). In addition, the study found that ribavirin therapy significantly reduced progression to LRTD [OR 0.19, 95% C.I. 0.05–0.75,
p
= 0.018]. Co-infections (OR 5.7, 95% C.I. 1.4–23.5,
p
= 0.015) and ALC < 0.2 × 10
9
/L (OR 17.7, 95% C.I. 3.6–87.1,
p
< 0.001) were independently associated with higher day + 100 after hPIV detection all-cause mortality. There were no significant differences in all-cause mortality and infectious mortality at day + 100 between the treated and untreated groups.
Conclusion
ALC, corticosteroids, and fever increased the risk for progression to LRTD while ribavirin decreased the risk. However, mortality was associated with ALC and co-infections. This study supports further research of ribavirin therapy for hPIV in the allo-HSCT setting.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38653955</pmid><doi>10.1007/s15010-024-02213-0</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8533-2562</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8126 |
| ispartof | Infection, 2024-10, Vol.52 (5), p.1941-1952 |
| issn | 0300-8126 1439-0973 1439-0973 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_858107 |
| source | Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List |
| subjects | Adult Aged Allografts Antiviral Agents - therapeutic use Cell number Community-Acquired Infections - drug therapy Community-Acquired Infections - mortality Community-Acquired Infections - virology Corticoids Corticosteroids Family Medicine Female Fever General Practice Health services Humans Impact analysis Infections Infectious Diseases Internal Medicine Lymphocytes Male Medicin och hälsovetenskap Medicine Medicine & Public Health Middle Aged Mortality Multivariate analysis Parainfluenza Paramyxoviridae Infections - drug therapy Paramyxoviridae Infections - mortality Respiratory tract Respiratory tract diseases Retrospective Studies Ribavirin Ribavirin - therapeutic use Risk Factors Stem cell transplantation Stem Cell Transplantation - adverse effects Stem cells Steroids Therapy Transplantation, Homologous - adverse effects Transplants & implants Treatment Outcome Viruses Young Adult |
| title | Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T19%3A59%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20Human%20Parainfluenza%20Virus%20infection%20in%20allogeneic%20stem%20cell%20transplantation%20recipients:%20possible%20impact%20of%20ribavirin%20therapy&rft.jtitle=Infection&rft.au=P%C3%A9rez,%20Ariadna&rft.date=2024-10-01&rft.volume=52&rft.issue=5&rft.spage=1941&rft.epage=1952&rft.pages=1941-1952&rft.issn=0300-8126&rft.eissn=1439-0973&rft_id=info:doi/10.1007/s15010-024-02213-0&rft_dat=%3Cproquest_swepu%3E3119852781%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c414t-c004fa15e787e7d58800afe1a5c0dd322901a89dc0555763c35779f14adfd2633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3119852781&rft_id=info:pmid/38653955&rfr_iscdi=true |